Vascarta Journey to Optimize Patient Care & Creating Vasceptor®

Join your host, Steve, the Director of Strategic Partnerships, as he engages in a compelling dialogue with the leaders of Vascarta, a trailblazing pharmaceutical company. This episode dives into the nuances of international clinical trials, the specialized compounding of Vascarta's product Vasceptor®. Tune in as Dr. Richard Prince, CEO of Vascarta shares insights from his extensive career in the life sciences industry and discusses the innovative approaches that set Vascarta apart. His colleague Dr. Joel Friedman also shares his expert insight. Prescribed to: Reduced pain Reduced systemic inflammation Vasceptor® Formulation Vasceptor® 8.5% topical/transdermal curcumin gel was developed with the intent to deliver the well-known anti-pain/inflammation benefits of curcumin. Active ingredient – curcumin 8.5%. Inactive ingredients: Myristic Acid; PEG. Unlike traditional curcumin topicals, Vasceptor’s® patented formulation enables 100X more curcumin solubility. This facilitates substantially greater and sustained penetration deep into the skin versus conventional gel, cream or ointment technology. Unlike curcumin orals, Vasceptor’s® curcumin accesses capillaries, our smallest blood vessels. Once there, Vasceptor® loads onto and into blood cells as well as into the plasma. These blood cells can then broadly distribute the beneficial curcumin which creates enhanced efficacy. Patients, doctors, and investors may benefit from awareness of this unique product. More about Vasceptor® by Vascarta: https://tccompound.com/vasceptor/ #pain #inflammation #curcumin #Vascarta